101% Stock Return vs 103% Profit Growth: What Drives Shilpa Medicare Ltd’s Multibagger Rally?

Multibagger Status and Benchmark Comparison

Over the past year, Shilpa Medicare Ltd has delivered a remarkable 100.73% return, vastly outperforming the Sensex, which declined by 4.77% during the same period. The stock’s outperformance is not limited to the last year; it has also posted strong gains over longer horizons, with 366.33% over three years and 199.70% over five years, compared to Sensex returns of 18.66% and 38.36% respectively. Even over a decade, the stock has outpaced the benchmark, returning 190.84% against the Sensex’s 175.93%. This positions Shilpa Medicare Ltd as a consistent outperformer in the Pharmaceuticals & Biotechnology sector.

Recent Quarterly Results and Growth Drivers

The company’s latest quarterly results reinforce the fundamental strength behind the rally. Net sales reached a record Rs 465.78 crore, while operating profit grew by 14.85% year-on-year. Notably, Shilpa Medicare Ltd has reported positive results for 12 consecutive quarters, signalling sustained operational momentum. The operating profit to interest coverage ratio stands at a robust 11.26 times, reflecting strong earnings relative to debt servicing costs. Return on capital employed (ROCE) for the half-year is at 10.52%, indicating moderate capital efficiency in generating returns.

The company’s annualised operating profit growth rate of 31.89% over recent years further underpins the earnings expansion. This growth trajectory is a key factor in the stock’s performance — Shilpa Medicare Ltd is not merely benefiting from market speculation but is delivering tangible improvements in profitability. However, the question remains: does this fundamental trajectory justify the current valuation premium?

Returns Versus Fundamentals: The PEG and P/E Analysis

The stock’s price-to-earnings (P/E) ratio currently stands at 56.21, significantly higher than the Pharmaceuticals & Biotechnology industry average of 36.64. This represents a premium of approximately 53% to the sector valuation. The price-to-earnings-to-growth (PEG) ratio, calculated using the 102.8% profit growth and the 101.41% stock return, is roughly 0.6, indicating that the stock is trading at a discount relative to its earnings growth rate. This suggests that the market is not excessively pricing in future growth beyond what the company has demonstrated.

Such a PEG ratio below 1 typically signals that the stock’s valuation is supported by earnings growth rather than speculative P/E expansion. The near equivalence of profit growth and stock return further confirms this. However, the elevated P/E ratio does imply that investors are paying a premium for the company’s earnings, reflecting confidence in sustained growth. Is this premium justified by the company’s operational metrics and sector positioning?

Long-Term Track Record: Consistent Compounder or Recent Spike?

Examining the longer-term returns, Shilpa Medicare Ltd has demonstrated consistent outperformance over three, five, and ten-year periods. The 366.33% return over three years and 199.70% over five years indicate a sustained compounder rather than a one-year anomaly. The 10-year return of 190.84% also surpasses the Sensex’s 175.93%, reinforcing the company’s track record of value creation.

This consistency suggests that the recent one-year surge is an acceleration of an existing trend rather than a sudden rerating. The company’s ability to maintain positive quarterly results for 12 consecutive periods supports this narrative. Does this long-term consistency reduce concerns about the sustainability of the recent rally?

Valuation Context: ROCE and Debt Metrics

While the ROCE of 10.52% is respectable, it is moderate for a stock trading at a P/E above 56. This suggests that the market is pricing in expectations of improved capital efficiency or higher returns in the future. The company’s debt-to-EBITDA ratio of 1.52 times indicates a manageable but notable leverage level, which could constrain financial flexibility.

Net sales have grown at an annual rate of 12.95% over the past five years, a modest pace compared to the operating profit growth of 31.89%. This divergence points to improving operational margins and cost efficiencies as key drivers of profitability. However, the average return on equity (ROE) of 3.58% signals relatively low profitability per unit of shareholder funds, which may temper enthusiasm for the valuation premium.

Conclusion: What the Data Shows

The 101% return over the last year is closely matched by a 102.8% increase in net profit, resulting in a PEG ratio of approximately 0.6. This indicates that Shilpa Medicare Ltd’s multibagger status is fundamentally supported rather than driven by speculative valuation expansion. The company’s consistent quarterly performance, record sales, and improving operating profit margins reinforce this view.

However, the elevated P/E ratio of 56.21 compared to the industry average of 36.64 means the stock trades at a significant premium, reflecting market expectations of continued above-average growth and improved capital returns. ROCE and ROE metrics suggest moderate capital efficiency and profitability, which investors should monitor closely. After a 101% rally in one year — is Shilpa Medicare Ltd still a stock to hold for the long term, or has the multibagger run exhausted the valuation gap? The full analysis weighs in.

Key Metrics Overview

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →